Genetic Tests May Pinpoint Who Should Get Roche And Genentech, Inc.'s Avastin, Indiana University School of Medicine Study
LONDON (Reuters) - Genetic tests could in future show who will respond best to Genentech and Roche's blockbuster cancer drug Avastin -- a positive development for patients but not necessarily for sales.